{"success":true,"data":{"pressRelease":{"id":"52849","rtpr_id":"nACS7G37fa","ticker":"NYMXF","exchange":"OTC","all_tickers":["NYMXF"],"title":"NYMOX Provides Current Update","author":"ACCESSWIRE","published_at":"2026-06-02T20:00:00.168Z","article_body":"IRVINE, CA / ACCESS Newswire (https://www.accessnewswire.com/) / June 2, 2026\n/ Nymox Pharmaceutical Corporation (\"Nymox\", \"The Company\") (OTCQB:NYMXF)\nreports that its plans for Nymozarfex (TM) are currently focused on\nre-submission in the US for marketing approval. The initial US submission was\nnot accepted to be reviewed.\n\nThe Company's subsequent 2 submissions to Denmark and UK agencies were both\naccepted for full review but were initially refused and will require updated\nre-submission and re-review if the Company decides to pursue EU approvals\nfurther. The UK refused the application after review, and while the Company\nwill not be appealing the UK decision at this time, updated re-submissions are\na possibility. The Company believes Nymozarfex (TM) has the necessary clinical\nand scientific data required to formulate the required re-submissions. The\nreviewers remained skeptical re: 1. the one-year persistence of the\nsignificant placebo effect, despite the well established fact that the\nNymozarfex non-oral placebo trial data was corroborated by the data in\npractically all non-oral BPH placebo groups in the entire published world\nliterature; and 2. re what are the practical benefits of longer-term efficacy\nin this chronic long-term condition; and despite the primary endpoint symptom\ntest scores being the universal endpoint used by urologists and agencies in\nthe field for many decades.\n\nNymox CEO stated \"Due to current financial limits, updated re-submissions will\nrequire additional financing. There remains great public demand for safe\ntreatments for BPH and early prostate cancer, without the distressing side\neffects and discomforts of approved treatments. The Company is confident that\nwith additional support, the treatments will become available to patients. The\nindependently audited overall double blind Phase 3 long-term data has a p\nvalue of .0003 vs placebo, which we consider to be more than adequately\nsolid.\"\n\nFor more information please contact info@nymox.com or 800-936-9669.\n\nForward Looking Statements\n\nTo the extent that statements contained in this press release are not\ndescriptions of historical facts regarding Nymox, they are forward-looking\nstatements reflecting the current beliefs and expectations of management made\npursuant to the safe harbor provisions of the Private Securities Litigation\nReform Act of 1995, including statements regarding the need for new options to\ntreat BPH and prostate cancer, the potential of Fexapotide to treat BPH and\nprostate cancer and the estimated timing of further developments for\nFexapotide. Such forward-looking statements involve substantial risks and\nuncertainties that could cause our clinical development program, future\nresults, performance or achievements to differ significantly from those\nexpressed or implied by the forward-looking statements. Such risks and\nuncertainties include, among others, the uncertainties inherent in the\nclinical drug development process, including the regulatory approval process,\nthe timing of Nymox's regulatory filings, Nymox's substantial dependence on\nFexapotide, Nymox's commercialization plans and efforts and other matters that\ncould affect the availability or commercial potential of Fexapotide. Nymox\nundertakes no obligation to update or revise any forward looking statements.\nFor a further description of the risks and uncertainties that could cause\nactual results to differ from those expressed in these forward-looking\nstatements, as well as risks relating to the business of Nymox in general, see\nNymox's current and future reports filed with the U.S. Securities and Exchange\nCommission, including its Annual Report on Form 20-F for the year ended\nDecember 31, 2024.\n\nSOURCE: Nymox Pharmaceutical Corporation\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/nymox-provides-current-update-1172760)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACS7G37fa","title":"NYMOX Provides Current Update","author":"ACCESSWIRE","ticker":"NYMXF","created":"2026-06-02T20:00:00.168Z","tickers":["NYMXF"],"exchange":"OTC","article_body":"IRVINE, CA / ACCESS Newswire (https://www.accessnewswire.com/) / June 2, 2026\n/ Nymox Pharmaceutical Corporation (\"Nymox\", \"The Company\") (OTCQB:NYMXF)\nreports that its plans for Nymozarfex (TM) are currently focused on\nre-submission in the US for marketing approval. The initial US submission was\nnot accepted to be reviewed.\n\nThe Company's subsequent 2 submissions to Denmark and UK agencies were both\naccepted for full review but were initially refused and will require updated\nre-submission and re-review if the Company decides to pursue EU approvals\nfurther. The UK refused the application after review, and while the Company\nwill not be appealing the UK decision at this time, updated re-submissions are\na possibility. The Company believes Nymozarfex (TM) has the necessary clinical\nand scientific data required to formulate the required re-submissions. The\nreviewers remained skeptical re: 1. the one-year persistence of the\nsignificant placebo effect, despite the well established fact that the\nNymozarfex non-oral placebo trial data was corroborated by the data in\npractically all non-oral BPH placebo groups in the entire published world\nliterature; and 2. re what are the practical benefits of longer-term efficacy\nin this chronic long-term condition; and despite the primary endpoint symptom\ntest scores being the universal endpoint used by urologists and agencies in\nthe field for many decades.\n\nNymox CEO stated \"Due to current financial limits, updated re-submissions will\nrequire additional financing. There remains great public demand for safe\ntreatments for BPH and early prostate cancer, without the distressing side\neffects and discomforts of approved treatments. The Company is confident that\nwith additional support, the treatments will become available to patients. The\nindependently audited overall double blind Phase 3 long-term data has a p\nvalue of .0003 vs placebo, which we consider to be more than adequately\nsolid.\"\n\nFor more information please contact info@nymox.com or 800-936-9669.\n\nForward Looking Statements\n\nTo the extent that statements contained in this press release are not\ndescriptions of historical facts regarding Nymox, they are forward-looking\nstatements reflecting the current beliefs and expectations of management made\npursuant to the safe harbor provisions of the Private Securities Litigation\nReform Act of 1995, including statements regarding the need for new options to\ntreat BPH and prostate cancer, the potential of Fexapotide to treat BPH and\nprostate cancer and the estimated timing of further developments for\nFexapotide. Such forward-looking statements involve substantial risks and\nuncertainties that could cause our clinical development program, future\nresults, performance or achievements to differ significantly from those\nexpressed or implied by the forward-looking statements. Such risks and\nuncertainties include, among others, the uncertainties inherent in the\nclinical drug development process, including the regulatory approval process,\nthe timing of Nymox's regulatory filings, Nymox's substantial dependence on\nFexapotide, Nymox's commercialization plans and efforts and other matters that\ncould affect the availability or commercial potential of Fexapotide. Nymox\nundertakes no obligation to update or revise any forward looking statements.\nFor a further description of the risks and uncertainties that could cause\nactual results to differ from those expressed in these forward-looking\nstatements, as well as risks relating to the business of Nymox in general, see\nNymox's current and future reports filed with the U.S. Securities and Exchange\nCommission, including its Annual Report on Form 20-F for the year ended\nDecember 31, 2024.\n\nSOURCE: Nymox Pharmaceutical Corporation\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/nymox-provides-current-update-1172760)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-06-02T20:00:00.221447053Z","server_sent_at_ms":1780430400221},"received_at":"2026-06-02T20:00:00.354Z","source_url":"https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/nymox-provides-current-update-1172760"},"analysis":{"id":"42284","press_release_id":"52849","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Regulatory refusals in UK and EU; US submission not accepted for review","Explicit statement that additional financing is required for re-submissions","Regulatory skepticism regarding placebo effect and clinical utility"],"eventType":"regulatory","narrative":"Nymox Pharmaceutical reports that its lead asset Nymozarfex faces significant regulatory headwinds, with the initial US submission not accepted for review and subsequent applications in Denmark and the UK being refused.\n\nRegulators expressed skepticism regarding the persistence of placebo effects and the practical benefits of long-term efficacy, despite the company citing a statistically significant p-value of 0.0003 from its Phase 3 data.\n\nThe CEO stated that updated re-submissions to pursue approvals will require additional financing, implying a near-term dilutive capital raise is necessary to continue the program.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Nymox faces regulatory setbacks and signals need for new capital to re-submit Nymozarfex."},"keyFigures":{"drugName":"Nymozarfex","phaseOfTrial":"Phase 3","customDimensions":{}},"quotedText":"Due to current financial limits, updated re-submissions will require additional financing.","namedEntities":{"people":[{"name":"Nymox CEO","role":"CEO"}],"products":["Nymozarfex","Fexapotide"],"companies":[{"name":"Nymox Pharmaceutical Corporation","ticker":"NYMXF","relationship":"filer"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"The company confirms its lead asset Nymozarfex was refused by UK and EU regulators and the initial US submission was not accepted for review. The CEO explicitly states that pursuing re-submissions requires additional financing, signaling a near-term dilutive capital raise is necessary to continue development."},"tickerRelevance":{"others":[],"primary":"NYMXF"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":["clinical_trial"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"regulatory_refusal_and_capital_need","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low"}},"event_type":"regulatory","event_type_secondary":["clinical_trial"],"sentiment":"bearish","material_impact_score":3,"narrative":"Nymox Pharmaceutical reports that its lead asset Nymozarfex faces significant regulatory headwinds, with the initial US submission not accepted for review and subsequent applications in Denmark and the UK being refused.\n\nRegulators expressed skepticism regarding the persistence of placebo effects and the practical benefits of long-term efficacy, despite the company citing a statistically significant p-value of 0.0003 from its Phase 3 data.\n\nThe CEO stated that updated re-submissions to pursue approvals will require additional financing, implying a near-term dilutive capital raise is necessary to continue the program.","key_figures":{"drugName":"Nymozarfex","phaseOfTrial":"Phase 3","customDimensions":{}},"named_entities":{"people":[{"name":"Nymox CEO","role":"CEO"}],"products":["Nymozarfex","Fexapotide"],"companies":[{"name":"Nymox Pharmaceutical Corporation","ticker":"NYMXF","relationship":"filer"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-02T20:02:00.017Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"regulatory_refusal_and_capital_need","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low"}},"durationMs":76623,"modelName":"george-droid-qwen-72b"}}